Skip to main
CING
CING logo

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate Inc. stands at a favorable position within the biopharmaceutical sector, primarily driven by the growing U.S. ADHD medication market, which has expanded approximately 8% annually, reaching around $18 billion in 2020. The company's recent announcement of positive topline results from the CTx-1301 trial indicates a meaningful advancement in its product pipeline, showcasing notable efficacy compared to a placebo. This momentum, alongside the potential to leverage its precision timed-release drug delivery platform for additional therapeutic areas, highlights significant upside opportunities in Cingulate's stock despite the inherent risks associated with clinical-stage development.

Bears say

Cingulate Inc reported a net loss of $4.8 million, corresponding to an earnings per share (EPS) of $(1.09), which was below both internal estimates and consensus expectations. The company faces multiple risks that could hinder its financial recovery, including significant balance sheet and liquidity challenges, along with uncertainties surrounding the efficacy and safety of its product candidates during clinical trials. Additionally, the potential for failure in gaining necessary regulatory approvals and suitable reimbursement, coupled with heightened competition and shifting macroeconomic conditions, further contribute to the negative outlook on Cingulate's stock.

Cingulate (CING) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.